Spyre Therapeutics, Inc.

NASDAQ:SYRE

Biotechnology

Healthcare
$101.46 +1.38%

+$1.21 today

Market cap
$9.64B
Beta
3.06
P/E (TTM)
-171.1
EPS (TTM)
-$0.52
52W Low $14.00High $91.04

Volume 1.37M

Average 1.17M

SYRE Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Spyre Therapeutics, Inc.NASDAQ: SYRE

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development growth accelerates

Q3 FY2026 research & development of $89.17M rose 97.1% year over year, ahead of the +46.3% change in trailing-twelve-month research & development. Sequentially, it rose 36.1% from the prior quarter. Over 3 fiscal years it compounded at +43.1% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +97.1% holds above the trailing-twelve-month pace of +46.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$89.17M+36.1% QoQ
Last fiscal yearDec 2025
$171.65M+5.4% YoY
LTMSep 2026
$259.72M+46.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+97.1%——
1 year+5.4%——
3-year CAGR+43.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
171.65M USD
Year-over-year change
+5.4%
4-year CAGR
+31.7%

Research & Development vs competitors

How SYRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +46.3% is the 4th highest of 9, against a peer median of +27.6%.
  • Research & development amounts to 287.0% of revenue for SYRE, versus a peer median of 677.9%.
SYRE Competitors
Research & Development for SYRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYRESpyre Therapeutics, Inc.LTM Sep 2026$259.72M USD+46.3%+43.1%287.0%
ABVXAbivax S.A.FY2025€177.76M EUR+21.3%+54.4%—
UPBUpstream Bio, Inc.LTM Mar 2026$147.57M USD+91.5%+94.3%4442.3%
ANABAnaptysBio, Inc.LTM Mar 2026$128.65M USD-23.4%+15.3%55.4%
IMUXImmunic, Inc.LTM Mar 2026$86.08M USD+3.9%+4.8%—
ARDXArdelyx, Inc.LTM Mar 2026$74.32M USD+33.9%+24.8%17.4%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$56.72M USD+60.6%-12.2%677.9%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€39.31M EUR+49.4%——
IFRXInflaRx N.V.LTM Mar 2026€22.87M EUR-34.8%-11.8%77989.1%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding SYRE) —+27.6%+15.3%677.9%

Competitors are the stored peer set for SYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.74M2.33M886K00
Cost of Revenue0000171.65M
Gross Profit18.74M2.33M886K0(171.65M)
Gross Margin100.0%100.0%100.0%——
Research & Development57.07M58.58M89.5M162.79M171.65M
Selling, General & Admin27.32M28.53M39.95M45.78M47.91M
Operating Expenses84.39M87.11M243.19M208.57M37.91M
Depreciation & Amortization1.58M1.96M744K010M
EBITDA(64.08M)(81.99M)(127.82M)(207.97M)(209.56M)
EBITDA Margin-342.0%-3520.3%-14426.6%——
Operating Income(65.65M)(84.78M)(242.3M)(208.57M)(209.56M)
Operating Margin-350.3%-3640.2%-27348.0%——
Interest Income111K837K6.15M21.31M24.89M
Interest Expense00000
Other Income / Expenses(11K)830K(96.51M)599K54.34M
Income Before Tax(65.66M)(83.95M)(338.82M)(207.97M)(155.22M)
Pre-Tax Margin-350.4%-3604.6%-38241.1%——
Income Tax Expense141K(136K)(26K)51K(15K)
Net Income(65.8M)(83.82M)(338.79M)(208.02M)(155.2M)
Net Margin-351.1%-3598.8%-38238.1%——
EPS (Basic)(25.02)(24.86)(46.15)(3.18)(1.98)
EPS (Diluted)(25.02)(24.86)(46.15)(3.18)(1.98)
Weighted Avg Shares2.63M3.37M6.9M47.03M64.06M
Weighted Avg Shares (Diluted)2.63M3.37M6.9M47.03M64.06M

Spyre Therapeutics, Inc.

NASDAQ:SYRE

Intrinsic Alpha fair value

Locked

Current Price

$101.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.